Loading
Latest filing published 10 Jul 2026 for Evommune, Inc., €12k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Kyle Carver across 2 companies, led by Evommune, Inc. and Kadmon Holdings, Inc. Over a trading history stretching from 9 November 2021 to 8 July 2026, the count stands at 6 filings.
Both buying and selling appear: 1 purchase worth €12k, against 1 sale worth €357k. Taken together, the sales exceed the purchases by €346k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant and 1 option exercise. Since January 2026: 1 purchase and 1 sale on the market.
The newest entry dates from 10 July 2026: an open-market purchase of €12k, in Evommune, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations